All systems operational
Q3 2022

Protective mechanism of quercetin and its derivatives in viral-induced respiratory illnesses

Wahyu Choirur Rizky · Muhammad Candragupta Jihwaprani · Mazhar Mushtaq
10.1186/s43168-022-00162-6 389 Views 10 Citations
10
Citations
389
Views
Abstract

AbstractGlobally, acute respiratory illnesses are the most commonly manifesting illness in all age group. The disease mostly affects the upper respiratory tract (URT) and is self-limiting. However, a small percentage progresses to lower respiratory tract infections (LRTI). The most important causative agents of severe LRTIs are bacteria and viruses. Various viruses can cause respiratory tract infections, being the most essential belonging to the Orthomyxoviridae, Paramyxoviridae, Picornaviridae, coronaviruses, and adenoviruses. Quercetin is classified as a flavonoid compound and was previously known to have antiviral, antibacterial, antioxidant, and anti-inflammatory activities. Some preclinical studies highlight quercetin could also interfere with coronavirus infection and modulate the release of pro-inflammatory cytokines. Since there is no comprehensive compilation addressing the antiviral activities of quercetin and its derivatives, this narrative review provides a summary of the preclinical evidence of their antiviral activities on respiratory illnesses induced by viruses other than coronaviruses. The literature research was performed in PubMed, Scopus, and Google Scholar. The results explain that quercetin has a wide range of actions in viral-induced respiratory illnesses including, but not limited to suppressing pro-inflammatory cytokines and chemokines, promoting antioxidant-related genes expression, blocking viral entry and replication, accelerating viral clearance, reducing the accumulation of alveolar macrophages, and reducing goblet cells marker and mucin gene expression.

Cite this Article (APA)
Wahyu, C. R., Muhammad, C. J., Mazhar, M. (2022). Protective mechanism of quercetin and its derivatives in viral-induced respiratory illnesses. Egyptian Journal of Bronchology. https://doi.org/10.1186/s43168-022-00162-6
Related Papers
Serum interleukin-6 in chronic obstructive pulmonary disease patients and its relation to severity a…
Fatma G. M. Hussein; Randa S. Mohammed; Rasha A. Khattab; Laila A. Al-Sharawy · 2022
24
cites
388
Criteria and potential predictors of severity in patients with COVID-19
Niveen E. Zayed; Ahmad Abbas; Samah Mohamad Lutfy · 2022
24
cites
388
Predictors of severity and mortality in COVID-19 patients
Hebatallah Hany Assal; Hoda M. Abdel-hamid; Sally Magdy; Maged Salah; Asmaa Ali; · 2022
19
cites
387
Lung health after tuberculosis: clinical and functional assessment in post-pulmonary tuberculosis Eg…
Nermeen A. Abdelaleem; Mostafa K. Ahmed; Marwan N. Mohamed; Hassan A. Bayoumi · 2022
8
cites
392
Access
View Full Text via DOI
Published in
ISSN 1687-8426
Quartile Q3
AMS Score 82
Field Medicine & Health Sciences
Publisher Springer (Biomed Central Ltd.)
Country 🇪🇬 Egypt
View Journal Profile →
Authors
Publication Details
Year 2022
Language English
Added 14 Aug 2026